44. Kongress der Deutschen Gesellschaft für Rheumatologie, 30. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie, 26. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie
31.08. - 03.09.2016, Frankfurt am Main
Poster Donnerstag, 01.09.2016
Posterwalk – Spondyloarthritiden II
Meeting Abstract
(SP.17)
[Full Text]
Verbesserungen der Gelenkergebnisse bei Psoriasis-Arthritis über einen Behandlungszeitraum von 4 Jahren mit Certolizumab Pegol bei Patienten mit und ohne vorherige TNF-Blocker-Exposition
Wollenhaupt J, Mease P, Fleischmann R, Deodhar A, Gladman D, Bengt H, Peterson L, van der Heijde D[Full Text]
Meeting Abstract
(SP.18)
[Full Text]
Autoantibodies against CD74 – A new diagnostic marker for Spondyloarthritis (SpA)
Matthias T, Schweikhard E, Reuter S, Köhler M, Georgi J, Baerlecken N, Witte T[Full Text]
Meeting Abstract
(SP.19)
[Full Text]
Treatment failure, treatment switching and health-related quality of life in patients with ankylosing spondylitis or psoriatic arthritis: results from a large multinational realworld sample in Europe and the USA
Alten RHE, Sullivan E, Blackburn S, Tian H, Gandhi K, Jugl S[Full Text]
Meeting Abstract
(SP.20)
[Full Text]
Secukinumab for the treatment of ankylosing spondylitis: comparative effectiveness results versus adalimumab using a matching-adjusted indirect comparison
Jugl S, Maksymowych W, Baeten D, Thom H, Cure S, Palaka E, Gandhi K, Richards HB[Full Text]
Meeting Abstract
(SP.21)
[Full Text]
Secukinumab for the treatment of psoriatic arthritis: comparative effectiveness results versus adalimumab up to 48 weeks using a matching-adjusted indirect comparison
Jugl S, McInnes I, Mease P, Thom H, Cure S, Palaka E, Gandhi K, Mpofu S[Full Text]
Meeting Abstract
(SP.22)
[Full Text]
Secukinumab for the treatment of psoriatic arthritis: comparative effectiveness results versus licensed biologics and apremilast from a network meta-analysis
Schulze-Koops H, McInnes I, Palaka E, Gandhi K, Mpofu S, Jugl S[Full Text]
Meeting Abstract
(SP.23)
[Full Text]
Effect of Secukinumab, an Interleukin-17A inhibitor, on Spinal Radiographic Changes Through 2 Years in Patients with Active Ankylosing Spondylitis: Results of the Phase 3 Study, MEASURE 1
Braun J, Baraliakos X, Sieper J, Emery P, Talloczy Z, Martin R, Richards HB[Full Text]
Meeting Abstract
(SP.24)
[Full Text]
Secukinumab Provides Rapid and Sustained Reductions in Dactylitis and Enthesitis in Patients with Psoriatic Arthritis: Analysis of Data from the Phase 3 Randomised, Multicentre, Double-blind, Placebo-controlled FUTURE 2 study
Sieper J, Kirkham B, Bhosekar V, Mpofu S, Gandhi K, Gaillez C[Full Text]